Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma
MALT Lymphoma of Stomach|Helicobacter Pylori Infection
DRUG: Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib|DRUG: Triple therapy for eradication of Helicobacter Pylori
6-months CR rate, the ratio of numbers of patients with complete response to all the participants receiving treatment, up to 6 months
3-months CR rate, the ratio of numbers of patients with complete response to all the participants, up to 3 months|2-year progression-free survival (PFS), the period from the date of patients sign informed consent to the observed progression of the disease or the occurrence of death for any reason, From date of patients sign informed consent until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 years|2-year event-free survival (EFS), the period from the date of patients sign informed consent to the observed event for any reason, From date of patients sign informed consent until the date of first documented event, progression or date of death from any cause, whichever came first, assessed up to 2 years|2-year overall survival rate, time between the date of patients sign informed consent and the date of death or the date of last follow-up time, From date of patients sign informed consent until the date of death or the date of last follow-up time, whichever came first, assessed up to 2 years|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Record the name of adverse events and number of participants with treatment-related adverse events as assessed by CTCAE v5.0, Throughout the treatment period, up to 6 months
Exploratory biomarkers, Biomarkers for predictive factors of efficacy at baseline or during the treatment, Throughout the treatment period, up to 2 years
This multicenter, open-label, randomized controlled trial is trying to evaluate the efficacy and safety of Orelabrutinib in the first-line treatment of HP-positive gastric MALT lymphoma